The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Pharmacyclics
 
Samuel A. Jacobs
No Relationships to Disclose
 
Hanna Kelly Sanoff
Research Funding - Bayer (Inst)
 
Deirdre Jill Cohen
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst)
 
Katherine A Guthrie
No Relationships to Disclose
 
Norah Lynn Henry
Research Funding - Abbvie (Inst); Innocrin Pharma (Inst); Pfizer (Inst)
 
Patricia A. Ganz
Leadership - Intrinsic LifeSciences (I)
Stock and Other Ownership Interests - Abbott Laboratories; GlaxoSmithKline; Intrinsic LifeSciences (I); Johnson & Johnson; Merck; Novartis; Pfizer; Silarus Therapeutics (I); Teva; xenon pharma (I)
Consulting or Advisory Role - Akebia Therapeutics (I); Ambys Medicines (I); American Regent (I); Astellas Pharma (I); Blue Note Therapeutics; Disc Medicine (I); GlaxoSmithKline (I); Global Blood Therapeutics (I); Gossamer Bio (I); InformedDNA; ION Pharma (I); Protagonist Therapeutics (I); Regeneron (I); Rockwell Medical Technologies Inc (I); Sierra Oncology (I); Vifor Pharma (I)
Research Funding - Sierra Oncology (I)
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I); Up-to-Date royalties for section editor on survivorship
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I)
 
Scott Kopetz
Stock and Other Ownership Interests - Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; Daiichi Sankyo; EMD Serono; EMD Serono; Genentech; HalioDx; Holy Stone Healthcare; Ipsen; Jacobio; Karyopharm Therapeutics; Lilly; Lutris; Merck; Natera; Navire; Novartis; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Honoraria - Schrodinger (I)
 
Charles David Blanke
No Relationships to Disclose
 
Norman Wolmark
No Relationships to Disclose
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Elion Oncology; Genentech; Merck
 
Thomas J. George
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Seagen (Inst); Tesaro (Inst)
 
Caio Max Sao Pedro Rocha Lima
Honoraria - Celgene; Eisai; Eisai; Taiho Pharmaceutical; Xcenda
Speakers' Bureau - Celgene; Eisai; Merck; Taiho Pharmaceutical
Research Funding - Boston Biomedical; Pharmacyclics; Rafael Pharmaceuticals